Shots:
- Accord BioPharma has launched Filkri, a biosimilar version of Neupogen (filgrastim), in the US following the FDA approval in Jan 2026
- Filkri was approved based on data showing its similarity to Neupogen, with no clinically meaningful differences. It is available in 300mcg/0.5mL & 480mcg/0.8mL PFS presentations, with pack sizes of one or 10 PFS per carton
- Filkri will be manufactured end-to-end by Intas & has received permanent CMS Q-code Q5172, effective Oct 1, 2026
Ref: PRnewswire | Image: Accord BioPharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
